Pharmamarketeer

US FDA approves Sandoz’s biosimilar Ziextenzo

Sandoz, a Novartis division and a global leader in biosimilars, announced that the US Food and Drug Administration (FDA) approved its biosimilar Ziextenzo (pegfilgrastim─bmez).

Medhc-fases-banner
Advertentie(s)